Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Prognostic markers in gliomas.

Marianne Labussiere1, Xiao-Wei Wang, Ahmed Idbaih

  • 1Pierre et Marie Curie University (Paris 6), Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière (CRICM) UMR-S975, Paris, France.

Future Oncology (London, England)
|May 15, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetic Resonance Imaging Features in Intramedullary Tumors: A Pictorial Review.

Biomedicines·2026
Same author

Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis.

HemaSphere·2026
Same author

Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.

European journal of haematology·2026
Same author

Early brain biopsy in neurological diseases of unknown etiology improves functional outcome.

European journal of internal medicine·2026
Same author

Neurofilament as a biomarker of neurodegeneration in childhood Langerhans cell histiocytosis: A feasibility study on 273 patients.

British journal of haematology·2026
Same author

Prognostic factors in adult patients with medulloblastoma.

Neuro-oncology practice·2026

Molecular markers like 1p19q codeletion, O(6)-methylguanine DNA methyltransferase (MGMT) status, and isocitrate dehydrogenases 1 and 2 (IDH1/IDH2) mutations are crucial for classifying diffuse gliomas. These markers enhance diagnostic objectivity and aid in ongoing clinical trial stratification.

Area of Science:

  • Neuro-oncology
  • Molecular Pathology
  • Cancer Genomics

Background:

  • Extensive molecular studies have refined glioma classification beyond traditional histology.
  • Key molecular markers are essential for accurate diagnosis and prognosis in diffuse gliomas.

Purpose of the Study:

  • To highlight the significance of specific molecular markers in glioma classification.
  • To emphasize the role of these markers in current and future clinical practice.

Main Methods:

  • Review of recent molecular studies in glioma diagnostics.
  • Analysis of established and emerging molecular markers including 1p19q codeletion, MGMT status, and IDH1/IDH2 mutations.

Main Results:

  • 1p19q codeletion, MGMT status, and IDH1/IDH2 mutations are the most pertinent molecular markers for diffuse gliomas.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Experiment Videos

Last Updated: Jun 13, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

  • IDH1 mutations are recognized as a major prognostic factor.
  • Clinical trials utilize these markers for patient stratification.

    • Conclusions:

    • Routine molecular marker analysis improves the objective classification of gliomas.
    • Further research is needed to determine the predictive value of IDH1/IDH2 mutations for treatment response.